Tarsus Pharmaceuticals (TARS) Cash & Current Investments (2019 - 2026)

Tarsus Pharmaceuticals' Cash & Current Investments history runs 8 years deep, the most recent figure standing at $102.2 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 74.95% year-over-year to $102.2 million; the TTM figure through Mar 2026 stood at $102.2 million (down 74.95% YoY), while the FY2025 annual figure was $184.2 million, down 36.78% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $102.2 million, down from $184.2 million in the prior quarter.
• The five-year high for Cash & Current Investments was $407.9 million in Q1 2025, with the low at $102.2 million in Q1 2026.
• The 5-year median for Cash & Current Investments is $245.4 million (2022), against an average of $260.3 million.
• The sharpest annual moves came in 2024 and 2026: Cash & Current Investments surged 81.55% in 2024, then tumbled 74.95% in 2026.
• Tarsus Pharmaceuticals' Cash & Current Investments stood at $217.0 million in 2022, then rose by 4.8% to $227.4 million in 2023, then advanced by 28.11% to $291.4 million in 2024, then slumped by 36.78% to $184.2 million in 2025, then slumped by 44.52% to $102.2 million in 2026.
• Business Quant data shows TARS's Cash & Current Investments at $102.2 million in Q1 2026, $184.2 million in Q4 2025, and $401.8 million in Q3 2025.